Hansson Pharmaceuticals: Grants Regeneron exclusive overseas license for GLP-1/GIP dual receptor agonist HS-20094 under development.

On June 2nd, Hanseng Pharmaceuticals announced that they have entered into a licensing agreement with Regeneron Pharmaceuticals, Inc., granting Regeneron the exclusive global license to develop, manufacture, and commercialize HS-20094. HS-20094 is an investigational GLP-1/GIP dual receptor agonist that is currently undergoing phase III clinical trials in China. Under the agreement, Hanseng Pharmaceuticals will receive an upfront payment of $80 million and potentially up to $1.93 billion in milestone payments based on the development, regulatory approval, and commercialization progress of the product, as well as a double-digit percentage royalty on future potential product sales.